sb 203580 has been researched along with E coli Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, X; Danner, RL; Eichacker, PQ; Ferreyra, GA; Fitz, Y; Hsu, LL; Li, Y; Mani, H; Su, J | 1 |
| Demirel, I; Mohlin, C; Persson, K; Säve, S; Svensson, L; Vumma, R | 1 |
2 other study(ies) available for sb 203580 and E coli Infections
| Article | Year |
|---|---|
SB203580, a p38 inhibitor, improved cardiac function but worsened lung injury and survival during Escherichia coli pneumonia in mice.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Cardiac Output; Echocardiography; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Escherichia coli Infections; Fluid Therapy; Imidazoles; Lipopolysaccharides; Lung Injury; Mice; Placebos; Pneumonia; Proportional Hazards Models; Pyridines; Survival Rate | 2010 |
Nitric oxide activates IL-6 production and expression in human renal epithelial cells.
Topics: Anthracenes; Epithelial Cells; Escherichia coli Infections; Flavonoids; Gene Expression; Humans; Imidazoles; Interleukin-1; JNK Mitogen-Activated Protein Kinases; Kidney; MAP Kinase Signaling System; Nitric Oxide; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; RNA Stability; RNA, Messenger | 2012 |